Marval Biosciences, Inc.

1302 Waugh, #842
Houston, TX 77019
281.802.4776 office

Website
www.marvalbiosciences.com

Marval Biosciences develops novel CT contrast agents that reduce toxicity to patients and improve imaging performance. These next-generation contrast agents will enable a much broader population of patients to use CT for diagnosis of cardiovascular diseases without fear of contrast-induced nephropathy, which can cause acute kidney failure, particularly in elderly and diabetic patients. Based in Houston, Texas, Marval was created through the licensing of intellectual property from the University of Texas Health Science Center at Houston, Georgia Institute of Technology, Case Western Reserve University, Cleveland State University and The University of Houston.